Welcome to our dedicated page for Ideaya Biosciences news (Ticker: IDYA), a resource for investors and traders seeking the latest updates and insights on Ideaya Biosciences stock.
IDEAYA Biosciences, Inc. develops precision medicine oncology therapies for molecularly defined cancer populations. The company’s news centers on targeted small-molecule programs, synthetic lethality research, antibody-drug conjugates and biomarker-guided clinical development across solid tumors.
Recurring updates include darovasertib clinical data in uveal melanoma, including combination work with crizotinib, as well as pipeline developments for programs such as IDE849, IDE161, IDE574 and IDE397. Company announcements also cover medical-meeting presentations, FDA regulatory interactions, clinical collaboration activity, quarterly financial results, cash runway commentary and equity compensation grants under Nasdaq inducement rules.
IDEAYA Biosciences (NASDAQ: IDYA) announced an Investor R&D Day in London on Monday, November 16, 2026, at 5:00 PM GMT, focused on MTAP/CDKN2A and KRAS development strategies in pancreatic cancer, including new preclinical data and combination approaches. The event will feature Dr. Frank McCormick of UCSF and requires advance registration for in-person and virtual attendance. IDEAYA will also participate in several major September 2026 healthcare and biopharma investor conferences in Boston and New York, with multiple fireside chats involving senior management and webcast access via the company’s investor website.
IDEAYA Biosciences (NASDAQ: IDYA) reported a successful FDA Type C meeting that informed the planned design of a global randomized Phase 3 registrational trial of IDE849, a DLL3-targeting TOP1 antibody-drug conjugate, in extensive stage small cell lung cancer (ES‑SCLC) with prior tarlatamab treatment.
IDEAYA is targeting Phase 3 initiation by year-end 2026, enrolling ~400 ES‑SCLC patients randomized 1:1 to IDE849 monotherapy versus investigator’s choice (topotecan or amrubicin). The primary endpoint for potential accelerated approval will be ORR by blinded independent central review; median overall survival will serve as the primary endpoint for potential full approval.
Ongoing Phase 1 work is evaluating 2.4 mg/kg and 3.5 mg/kg IV Q3W to select the recommended Phase 3 dose. IDE849 is also being studied in combinations with AstraZeneca’s Imfinzi and IDEAYA’s PARG inhibitor IDE161 to inform a potential first‑line SCLC Phase 3 trial design.
IDEAYA Biosciences (NASDAQ: IDYA) disclosed that on August 27, 2026, its Board Compensation Committee granted non-qualified stock options for an aggregate 62,800 shares of common stock to two newly hired employees under the 2023 Employment Inducement Incentive Award Plan, in line with Nasdaq Listing Rule 5635(c)(4).
The options have a $41.77 exercise price, a 10-year term, and vest over four years: 25% after one year and the remaining 75% in equal monthly installments over the following three years, subject to continued service.
IDEAYA Biosciences (NASDAQ: IDYA) announced a clinical collaboration with Genentech, a member of the Roche Group, to evaluate IDEAYA’s Phase 1 MTA-cooperative PRMT5 inhibitor IDE892 in combination with Genentech’s KRAS G12D inhibitor GDC-7035 (RG6620) in patients with MTAP-deleted, KRAS G12D-mutant pancreatic ductal adenocarcinoma (PDAC).
Genentech will sponsor the combination trial and IDEAYA will supply IDE892, with joint governance overseeing the study. According to IDEAYA, IDE892 shows approximately 1,400-fold selectivity for MTA-PRMT5 versus SAM-PRMT5 cooperative binding, favorable CYP450 interaction data, and is already in Phase 1 dose escalation and combination cohorts across MTAP-deleted solid tumors.
IDEAYA Biosciences (Nasdaq: IDYA) reported second quarter 2026 results and a broad business update. The registrational Phase 2/3 OptimUM-02 trial of darovasertib plus crizotinib in first-line HLA*A2:01‑negative metastatic uveal melanoma met its primary endpoint, improving median PFS to 6.9 vs 3.1 months versus investigator’s choice (HR 0.42; p<0.0001). An NDA filing under FDA’s real-time oncology review is underway, with completion targeted in H2 2026.
IDEAYA ended June 30, 2026 with $1.24 billion in cash, cash equivalents and marketable securities, and maintained cash runway guidance into 2030. Q2 2026 collaboration revenue was $8.9 million, R&D expenses $108.7 million, G&A expenses $22.5 million, and net loss $112.5 million.
IDEAYA Biosciences (NASDAQ: IDYA) reported that on July 30, 2026, its Board Compensation Committee granted non-qualified stock options to purchase an aggregate of 260,200 shares of common stock to fourteen newly hired employees under the 2023 Employment Inducement Incentive Award Plan, in accordance with Nasdaq Listing Rule 5635(c)(4). The options have a $36.40 exercise price, a 10-year term, and vest over four years, with 25% vesting after one year and the remaining 75% vesting in equal monthly installments over the following three years, subject to continued service.
IDEAYA Biosciences (NASDAQ: IDYA) reported initiation of Part 2 monotherapy expansion in its Phase 1/2 trial of IDE892, an MTA-cooperative PRMT5 inhibitor, in MTAP-deleted solid tumors, focusing on NSCLC and PDAC. Monotherapy expansion begins at projected efficacious human exposures achieving 24-hour EC90 target coverage, while dose escalation continues and a maximum tolerated dose has not yet been reached.
IDEAYA highlights IDE892’s approximately 1,400-fold selective MTA-PRMT5 binding versus SAM-PRMT5, lack of brain penetration, and favorable CYP profile, and is advancing IDE892 combinations with IDE397 and Roche’s pan-RAS inhibitor RG6505, alongside a CDKN2A program targeting an IND in 1H 2027.
IDEAYA Biosciences (Nasdaq: IDYA) announced that three darovasertib abstracts and one IDE849 abstract have been accepted for poster presentation at the ESMO 2026 Congress, to be held October 23–27, 2026, in Madrid, Spain.
The company will present data updates from multiple ongoing uveal melanoma trials, including the registrational Phase 2/3 OptimUM-02 study in HLA*A2:01‑negative metastatic uveal melanoma, the Phase 2 OptimUM-01 study in HLA*A2:01‑positive metastatic uveal melanoma, and the Phase 2 OptimUM-09 neoadjuvant study in primary uveal melanoma. IDEAYA’s partner Hengrui Pharma will present long‑term results from a Phase 1 study of IDE849 (SHR‑4849), a DLL3‑targeting TOP1 antibody‑drug conjugate, in relapsed small cell lung carcinoma and other neuroendocrine carcinomas. Named academic investigators from Australia, France, the United States, and China are listed as presenting authors for each poster.
IDEAYA Biosciences (NASDAQ: IDYA) granted non-qualified stock options for an aggregate 98,000 common shares to four newly hired employees on June 25, 2026. The awards were made under the 2023 Employment Inducement Incentive Award Plan in line with Nasdaq Listing Rule 5635(c)(4).
The options have a $36.29 exercise price, a 10-year term, and vest over four years: 25% after one year and the remaining 75% in equal monthly installments over three years, subject to continued service.
IDEAYA Biosciences (NASDAQ: IDYA) announced that its Board of Directors has elected Yujiro S. Hata as Chairman of the Board, effective June 17, 2026. Hata also serves as President, Chief Executive Officer and director. Terry Rosen, Ph.D., will serve as Lead Independent Director.
IDEAYA is described as a leading precision medicine oncology company with an extensive clinical pipeline and ongoing commercial launch preparations. Hata, who founded IDEAYA over a decade ago, emphasized advancing cancer research and delivering breakthrough therapies for patients with high unmet medical needs.